Art. -Nr.: HY-10320

Doramapimod

(Synonyms: BIRB 796)

52 Cited Publications

Kundenbewertung

Based on 52 publication(s) in Google Scholar

Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC₅₀ for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits B-Raf with an IC₅₀ of 83 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.93%
CAS. Nr.: 285983-48-4
Formel: C₃₁H₃₇N₅O₃
Molecular Weight:527.66

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Doramapimod Chemical Structure

CAS. Nr.: 285983-48-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (52)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]

p38α

38 nM (IC₅₀)

p38β

65 nM (IC₅₀)

p38δ

520 nM (IC₅₀)

p38γ

200 nM (IC₅₀)

B-Raf

83.4 nM (IC₅₀)

Abl

14600 nM (IC₅₀)

p38 MAP kinase

0.1 nM (Kd)

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle Raf Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
PBMC	IC₅₀	15 nM Compound: BIRB-796	Antiinflammatory activity in LPS-stimulated human isolated PBMC assessed as inhibition of TNFalpha production preincubated for 1 hr prior to LPS-challenge by ELISA Antiinflammatory activity in LPS-stimulated human isolated PBMC assessed as inhibition of TNFalpha production preincubated for 1 hr prior to LPS-challenge by ELISA	[PMID: 21888439]
PBMC	IC₅₀	30 nM Compound: BIRB-796	Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA	[PMID: 18602262]
THP-1	EC₅₀	18 nM Compound: 45	Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in THP-1 cells Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in THP-1 cells	[PMID: 12086485]
THP-1	IC₅₀	0.013 μM Compound: BIRB-796	Inhibition of LPS-induced TNFalpha production in human THP1 cells Inhibition of LPS-induced TNFalpha production in human THP1 cells	[PMID: 18325768]
THP-1	IC₅₀	18 nM Compound: 1, BIRB-796	Inhibition of LPS-induced TNFalpha production in human THP1 cells Inhibition of LPS-induced TNFalpha production in human THP1 cells	[PMID: 19356929]
THP-1	IC₅₀	18 nM Compound: BIRB-796	Inhibition of LPS-induced TNFalpha production in THP1 cells Inhibition of LPS-induced TNFalpha production in THP1 cells	[PMID: 17560108]
THP-1	IC₅₀	18 nM Compound: BIRB-796	Inhibition of LPS-stimulated TNFalpha production in human THP1 cells Inhibition of LPS-stimulated TNFalpha production in human THP1 cells	[PMID: 18462940]
U-937	IC₅₀	15 nM Compound: 4; BIRB-796	Antiinflammatory activity in differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS-stimulation for 4 hrs by sandwich ELISA relative to vehicle-treated control Antiinflammatory activity in differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS-stimulation for 4 hrs by sandwich ELISA relative to vehicle-treated control	[PMID: 26800309]

In Vitro

Doramapimod (BIRB 796) is usually associated with inflammation because of its role in T-cell proliferation and cytokine production^[1].
Doramapimod (BIRB 796) blocks the stress-induced phosphorylation of the scaffold protein SAP97, further establishing that this is a physiological substrate of SAPK3/p38γ. The binding of Doramapimod to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The mean xenograft weigh of Doramapimod (BIRB 796) is lighter than control. The inhibition rate of Doramapimod is 1.93%^[4].
The Doramapimod (BIRB 796) treatment slightly reduces blood pressure (166±7 mm Hg at week 7; P<0.05), whereas SD rats are normotensive (123±3 mm Hg). Despite the reduction in blood pressure, untreated and Doramapimod-treated dTGRs have similar heart weight and cardiac hypertrophy indices (heart-to-tibia ratio), which are significantly higher compare with nontransgenic SD rats (310±6 versus 307±6 versus 206±5 mg/cm, respectively; P<0.05)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 285983-48-4
Appearance Solid
Molecular Weight 527.66
Formel C₃₁H₃₇N₅O₃
Color Off-white to gray
SMILES

O=C(NC1=CC(C(C)(C)C)=NN1C2=CC=C(C)C=C2)NC3=C4C=CC=CC4=C(OCCN5CCOCC5)C=C3
Synonyms

BIRB 796
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (52)

All IP2D/3D Cell Culture and DifferentiationWBIF

Sort by:

Journal Impact Factor

Nature

UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. [Abstract]

2019 Jul;571(7763):127-131. PMID: 31243371

Doramapimod purchased from MedChemExpress. Usage Cited in: Nature. 2019 Jul;571(7763):127-131. [Abstract]

BIRB 796 (1 μM, 4.5 h) did not abrogate EGF-induced pUGDH in A549 cells stably expressing Flag–UGDH.
Cell Res

Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. [Abstract]

2020 Jul;30(7):574-589. PMID: 32341413

Doramapimod purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Jul;30(7):574-589. [Abstract]

Birb 796 (0.1, 0.3, 1, and 3 μM, 3 days) impaired the ability of SSK1 (0.5 μM,3 days) to specifically kill senescent HUVEC.
Nat Immunol

Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response. [Abstract]

2025 Oct;26(10):1660-1672. PMID: 40954252
Exp Mol Med

MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β. [Abstract]

2021 Sep;53(9):1366-1378. PMID: 34548615
Redox Biol

CARM1 phosphorylation at S595 by p38γ MAPK drives ROS-mediated cellular senescence. [Abstract]

2024 Sep 6:76:103344. PMID: 39265499

Doramapimod purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Sep 6:76:103344. [Abstract]

BIRB 796 (DORA, 10 μM, 4 h) inhibited the expression of p-p38 MAPK induced by LPS (1000 ng/mL) in 10T1/2 cells.

Doramapimod purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Sep 6:76:103344. [Abstract]

BIRB 796 (DORA, 10 μM, 4 h) inhibited the mitochondrial recruitment of DRP1 and the fission induced by LPS (1000 ng/mL) in 10T1/2 cells.
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Cell Rep Med

Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. [Abstract]

2025 Sep 19:102357. PMID: 40975064
Engineering

2025 Mar 4.

Doramapimod purchased from MedChemExpress. Usage Cited in: Engineering. 2025 Mar 4.

BIRB 796 (10 μM, 36 h) inhibited the expression of p-p38 MAPK induced by LPS (200 ng/mL) in THP-1 cells.
Cell Death Dis

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax. [Abstract]

2022 Oct 8;13(10):860. PMID: 36209148
Cell Death Dis

p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. [Abstract]

2016 Feb 25;7(2):e2119. PMID: 26913608
Phytomedicine

Complementary roles and synergy of the Ephedra-Glycyrrhiza herb pair across murine models of respiratory symptoms and poly(I:C)-induced pneumonia. [Abstract]

2026 Feb:151:157795. PMID: 41539102
EBioMedicine

PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. [Abstract]

2015 Nov 19;2(12):1944-56. PMID: 26844273
Br J Anaesth

Kappa opioid receptor internalisation-induced p38 nuclear translocation suppresses glioma progression. [Abstract]

2025 Mar;134(3):759-771. PMID: 39741108
Proc Natl Acad Sci U S A

Activation of the NLRP1 inflammasome in human keratinocytes by the dsDNA mimetic poly(dA:dT). [Abstract]

2023 Jan 31;120(5):e2213777120. PMID: 36693106
Dev Cell

Endoderm development requires centrioles to restrain p53-mediated apoptosis in the absence of ERK activity. [Abstract]

2021 Dec 20;56(24):3334-3348.e6. PMID: 34932949
Immun Ageing

p38 mitogen-activated protein kinase drives senescence in CD4+ T lymphocytes and increases their pathological potential. [Abstract]

2025 Jul 15;22(1):30. PMID: 40665343
EMBO Mol Med

Portimine A toxin causes skin inflammation through ZAKα-dependent NLRP1 inflammasome activation. [Abstract]

2025 Mar;17(3):535-562. PMID: 39948420
Cell Prolif

Rack1-mediated ferroptosis affects hindgut development in rats with anorectal malformations: Spatial transcriptome insights. [Abstract]

2024 Jul;57(7):e13618. PMID: 38523594
Anal Chem

Identifying Protein-Drug Interactions in Cell Lysates Using Histidine Hydrogen Deuterium Exchange. [Abstract]

2021 Nov 16;93(45):14985-14995. PMID: 34735131
Life Sci

OASL activates MAPK to drive psoriatic pathogenesis: Astilbin targeting this axis improves metabolic-inflammation crosstalk. [Abstract]

2025 May 11:123698. PMID: 40360089
Cells

SB202190 Predicts BRAF-Activating Mutations in Primary Colorectal Cancer Organoids via Erk1-2 Modulation. [Abstract]

2023 Feb 20;12(4):664. PMID: 36831331
Eur J Pharmacol

Adenine suppresses inflammatory response in vascular smooth muscle cells via modulating AMPK/p53/NF-κB cascade. [Abstract]

2025 Oct 10:1007:178239. PMID: 41075915
Cancer Biol Ther

Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. [Abstract]

2022 Dec 31;23(1):69-82. PMID: 35000525
Chem Biol Interact

A novel non-nad-based PARP1 inhibitor, Japoflavone B, triggered Caspase-3/GSDME-mediated pyroptosis through ROS/p38/p53 pathway in NSCLC. [Abstract]

2025 Oct 22:420:111693. PMID: 40754060
PLoS Pathog

The non-structural protein of SFTSV activates NLRP1 and CARD8 inflammasome through disrupting the DPP9-mediated ternary complex. [Abstract]

2025 Jul 3;21(7):e1013258. PMID: 40608794
Sci Rep

Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma. [Abstract]

2025 Jul 2;15(1):23648. PMID: 40603446
Toxics

Evaluation of THP-1 and Jurkat Cell Lines Coculture for the In Vitro Assessment of the Effects of Immunosuppressive Substances. [Abstract]

2024 Aug 19;12(8):607. PMID: 39195709
Transl Oncol

TMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway. [Abstract]

2022 May:19:101391. PMID: 35279540
Cell Signal

TNFR1 links TNF exocytosis to TNF production in allergen-activated RBL-2H3 cells. [Abstract]

2023 May:105:110607. PMID: 36690134
iScience

2025 Dec 26.
iScience

2025 Dec 9.
Clin Immunol

PLK2 facilitates Mycobacterium tuberculosis clearance via p38 MAPK-mediated ROS production. [Abstract]

2026 Jun:285:110705. PMID: 41962814
Biol Reprod

KAT2A contributes to premature ovarian insufficiency by activating the P38/MAPK signaling pathway to drive granulosa cell dysfunction†. [Abstract]

2026 Feb 20:ioag038. PMID: 41717786
Tissue Cell

U0126 induces osteoclast differentiation via the p38-NFATc-1 signaling pathway. [Abstract]

2025 Dec 5:99:103263. PMID: 41365188
Tissue Cell

Asiatic acid reverses cisplatin resistance in A549/DDP cells by activating the P38 MAPK/Slug pathway. [Abstract]

2025 Sep 17:98:103145. PMID: 41014726
Chin J Integr Med

Liang-Ge-San Decoction Ameliorates Acute Respiratory Distress Syndrome via Suppressing p38MAPK-NF-κ B Signaling Pathway. [Abstract]

2025 Jul;31(7):613-623. PMID: 39636495
Tissue Cell

The Shh-p38-NFATc1 signaling pathway is essential for osteoclastogenesis during tooth eruption. [Abstract]

2024 Nov 28:92:102643. PMID: 39612595
Theriogenology

RNA-seq analysis of the biological process and regulatory signal of TGF-β1-mediated changes in ovarian granulosa cells in small-tail Han sheep. [Abstract]

2024 Dec 2:234:9-18. PMID: 39631254
Discov Oncol

Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD. [Abstract]

2024 Nov 19;15(1):678. PMID: 39560891
Onco Targets Ther

Resveratrol, an activator of SIRT1, induces protective autophagy in non-small-cell lung cancer via inhibiting Akt/mTOR and activating p38-MAPK. [Abstract]

2018 Nov 2;11:7777-7786. PMID: 30464525
In Vitro Cell Dev Biol Anim

Cadmium-induced nucleus pulposus derived mesenchymal stem cells apoptosis via MAPK signaling pathway contributes to IVD degeneration. [Abstract]

2025 Oct 17. PMID: 41107668
bioRxiv

2026 Jan 25.
bioRxiv

Global Landscape of Human Kinase Motifs in Viral Proteomes. [Abstract]

2025 Jun 3:2025.06.02.657064. PMID: 40502089
bioRxiv

A discrete region of the D4Z4 is sufficient to initiate epigenetic silencing. [Abstract]

2025 Feb 23:2025.02.19.639175. PMID: 40027792
bioRxiv

2025 January 31.
Patent

US20240263208A1.
bioRxiv

2024 Mar 13.
Biomed Pharmacother

Inhibiting the MAPK pathway improves heart failure with preserved ejection fraction induced by salt-sensitive hypertension. [Abstract]

2024 Jan:170:115987. PMID: 38056241
Oxid Med Cell Longev

JFD, a Novel Natural Inhibitor of Keap1 Alkylation, Suppresses Intracellular Mycobacterium Tuberculosis Growth through Keap1/Nrf2/SOD2-Mediated ROS Accumulation. [Abstract]

2023 Feb 10:2023:6726654. PMID: 36819778
Curr Protoc Cell Biol

An On-Chip Method for Long-Term Growth and Real-Time Imaging of Brain Organoids. [Abstract]

2018 Dec;81(1):e62. PMID: 30239150
Dis Markers

Knockdown of Heparanase Suppresses Invasion of Human Trophoblasts by Activating p38 MAPK Signaling Pathway. [Abstract]

2018 Apr 17:2018:7413027. PMID: 29849826
Technische Universitat Dresden

2017.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (189.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 33.33 mg/mL (63.17 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8952 mL

9.4758 mL

18.9516 mL

5 mM

0.3790 mL

1.8952 mL

3.7903 mL

10 mM

0.1895 mL

0.9476 mL

1.8952 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (3.94 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[3]

Human embryonic kidney (HEK) 293 and HeLa cells are exposed to 0.5 M sorbitol for 30 min or 100 ng/mL EGF for 10 min and then lysed in buffer A (50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 50 mM sodium β-glycerophosphate, 5 mM pyrophosphate, 0.27 M sucrose, 0.1 mM phenylmethylsulfonyl fluoride, 1% (v/v) Triton X-100) plus 0.1% (v/v) 2-mercaptoethanol and Complete proteinase inhibitor mixture. Lysates are centrifuged at 18,000× g for 5 min at 4°C, and the supernatants are removed, quick-frozen in liquid nitrogen, and stored at -20°C until use. When required, cells are preincubated for 1 h without or with 10 μM SB 203580 or 10 μM PD 184352 or with different concentrations of Doramapimod for the times indicated in the figures^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]^[5]

Mice^[4]
Athymic nude mice (BALB/c-nu/nu), 6 to 8 weeks of age and weighing 18 to 24 g, are used. The mice are treated with Doramapimod (10 mg/kg p.o., every 3 days×5). The body weights of the animals and the two perpendicular tumor diameters (A and B) are recorded every 3 days, and the tumor volume (V) is estimated.
Rats^[5]
Male transgenic dTGRs (RCC Ltd) and age-matched nontransgenic Sprague-Dawley (SD) rats (MDC) are use. 2 different protocols are performed. In protocol 2, untreated dTGR (n=15), dTGR+BIRB796 (30 mg/kg per day in the diet for 3 weeks; n=11), and SD (n=8 each group) rats are analyzed. Systolic blood pressure is measured weekly by tail cuff. Twenty-four-hour urine samples are collected in metabolic cages from weeks 5 to 7. Serum is collected at week 7. Serum creatinine and cystatin C are measured by clinical routine assays. Urinary rat albumin is determined by enzyme-linked immunosorbent assay. The aim of protocol 2 is to focus on electrophysiological alterations and mortality. Untreated dTGR (n=10), dTGR+BIRB796 (n=10), and SD (n=10) rats are studied up to week 8.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Dietrich J, et al. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5738-48 [Content Brief]

[2]. Cicenas J, et al. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers (Basel). 2017 Dec 21;10(1). pii: E1. [Content Brief]

[3]. Kuma Y, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem, 2005, 280(20), 19472-19479. [Content Brief]

[4]. He D, et al. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PLoS One. 2013;8(1):e54181. [Content Brief]

[5]. Park JK, et al. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2007 Mar;49(3):481-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	1.8952 mL	9.4758 mL	18.9516 mL	47.3790 mL
	5 mM	0.3790 mL	1.8952 mL	3.7903 mL	9.4758 mL
	10 mM	0.1895 mL	0.9476 mL	1.8952 mL	4.7379 mL
	15 mM	0.1263 mL	0.6317 mL	1.2634 mL	3.1586 mL
	20 mM	0.0948 mL	0.4738 mL	0.9476 mL	2.3689 mL
	25 mM	0.0758 mL	0.3790 mL	0.7581 mL	1.8952 mL
	30 mM	0.0632 mL	0.3159 mL	0.6317 mL	1.5793 mL
	40 mM	0.0474 mL	0.2369 mL	0.4738 mL	1.1845 mL
	50 mM	0.0379 mL	0.1895 mL	0.3790 mL	0.9476 mL
	60 mM	0.0316 mL	0.1579 mL	0.3159 mL	0.7896 mL
DMSO	80 mM	0.0237 mL	0.1184 mL	0.2369 mL	0.5922 mL
DMSO	100 mM	0.0190 mL	0.0948 mL	0.1895 mL	0.4738 mL

Keywords

Doramapimod

52 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Doramapimod

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Doramapimod

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle Raf Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (52)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Doramapimod Related Classifications

HY-10320 Related Classifications